NEW YORK, Oct. 11, 2013 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in OvaScience, Inc. ("OvaScience" or the "Company") (Nasdaq:OVAS) of the November 15, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain executives.
A complaint has been filed on behalf of all persons who purchased OvaScience securities between February 25, 2013 and September 10, 2013 (the "Class Period").
The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning business, operational, and compliance policies. Specifically, the action focuses on whether OvaScience misrepresented to the FDA and the investing public that its AUGMENT technology qualified for 361 HCT/P designation and therefore did not need FDA licensure in order to be tested and marketed.
On September 10, 2013, the Company announced that it would suspend enrollment of AUGMENT in the U.S. after receiving an "untitled" letter from the FDA questioning the designation of AUGMENT as 361 HCT/P.
Following this news, OvaScience's stock declined by $3.32 or over 23%.
Request more information now by clicking here: www.faruqilaw.com/OVAS. There is no cost or obligation to you.
Take Action
If you invested in OvaScience stock or options between February 25, 2013 and September 10, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/OVAS. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding OvaScience's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.